Treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting second-generation antipsychotic.
2003 (English)In: J Clin Psychiatry, ISSN 0160-6689, Vol. 64, no 10, 1250-7 p.Article in journal (Refereed) Published
Place, publisher, year, edition, pages
2003. Vol. 64, no 10, 1250-7 p.
Administration; Oral, Adolescent, Adult, Adverse Drug Reaction Reporting Systems, Aged, Aged; 80 and over, Antipsychotic Agents/*administration & dosage/adverse effects, Comparative Study, Delayed-Action Preparations, Dose-Response Relationship; Drug, Drug Administration Schedule, Drug Therapy; Combination, Dyskinesia; Drug-Induced/diagnosis/etiology, Female, Humans, Injections; Intramuscular, Male, Middle Aged, Neurologic Examination/drug effects, Psychiatric Status Rating Scales, Research Support; Non-U.S. Gov't, Risperidone/*administration & dosage/adverse effects, Schizophrenia/diagnosis/*drug therapy, Schizophrenic Psychology, Treatment Outcome
IdentifiersURN: urn:nbn:se:uu:diva-74912PubMedID: 14658976OAI: oai:DiVA.org:uu-74912DiVA: diva2:102822